home / stock / teva / teva quote
Last: | $16.81 |
---|---|
Change Percent: | 0.18% |
Open: | $16.31 |
Close: | $16.81 |
High: | $16.88 |
Low: | $16.31 |
Volume: | 6,572,718 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$16.81 | $16.31 | $16.81 | $16.88 | $16.31 | 6,572,718 | 07-19-2024 |
$16.34 | $16.5 | $16.34 | $16.875 | $16.3 | 11,501,669 | 07-18-2024 |
$16.38 | $16.61 | $16.38 | $16.7 | $16.32 | 8,822,006 | 07-17-2024 |
$16.65 | $17.16 | $16.65 | $17.325 | $16.64 | 8,416,811 | 07-16-2024 |
$17.08 | $17.4 | $17.08 | $17.4 | $17.01 | 5,732,287 | 07-15-2024 |
$17.28 | $17.13 | $17.28 | $17.395 | $17.065 | 7,440,267 | 07-12-2024 |
$17.1 | $17 | $17.1 | $17.23 | $16.92 | 11,986,140 | 07-11-2024 |
$16.98 | $16.2 | $16.98 | $17 | $16.075 | 13,868,166 | 07-10-2024 |
$15.81 | $16.42 | $15.81 | $16.42 | $15.68 | 11,806,843 | 07-09-2024 |
$16.36 | $16.5 | $16.36 | $16.6 | $16.32 | 5,806,288 | 07-08-2024 |
$16.4 | $16.65 | $16.4 | $16.73 | $16.32 | 6,547,407 | 07-05-2024 |
$16.82 | $16.52 | $16.82 | $16.845 | $16.4105 | 3,979,086 | 07-04-2024 |
$16.82 | $16.52 | $16.82 | $16.845 | $16.4105 | 3,979,086 | 07-03-2024 |
$16.55 | $16.27 | $16.55 | $16.62 | $16.1 | 7,818,280 | 07-02-2024 |
$16.34 | $16.37 | $16.34 | $16.55 | $15.62 | 18,722,248 | 07-01-2024 |
$16.25 | $16.38 | $16.25 | $16.47 | $16.155 | 7,805,333 | 06-28-2024 |
$16.26 | $16.5 | $16.26 | $16.56 | $16.22 | 6,462,208 | 06-27-2024 |
$16.25 | $16.5 | $16.25 | $16.57 | $16.16 | 8,568,631 | 06-26-2024 |
$16.5 | $16.49 | $16.5 | $16.59 | $16.3701 | 12,386,537 | 06-25-2024 |
$16.49 | $16.83 | $16.49 | $16.91 | $16.46 | 7,564,973 | 06-24-2024 |
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...